Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Methylphenidate augmentation therapy in schizophrenia.

M D Carpenter1, B G Winsberg, L A Camus

  • 1Nathan S. Kline Institute for Psychiatric Research, Orangeburg, New York 10962.

Journal of Clinical Psychopharmacology
|August 1, 1992
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Patient satisfaction and impact of salivary flow rate on effectiveness of xerostomia products.

Oral surgery, oral medicine, oral pathology and oral radiology·2022
Same author

Investigation of binaural interference in normal-hearing and hearing-impaired adults.

Journal of the American Academy of Audiology·2000
Same author

Association of the dopamine transporter gene (DAT1) with poor methylphenidate response.

Journal of the American Academy of Child and Adolescent Psychiatry·1999
Same author

Community violence and inpatient assaults: neurobiological deficits.

The Journal of neuropsychiatry and clinical neurosciences·1998
Same author

Electrophysiological indices of information processing in methylphenidate responders.

Biological psychiatry·1997
Same author

Self-injurious behavior in a state psychiatric hospital.

Hospital & community psychiatry·1994
Same journal

Aripiprazole Withdrawal-Associated Restless Legs Syndrome During Clozapine Treatment in an Adolescent With Schizoaffective Disorder: A Case Report.

Journal of clinical psychopharmacology·2026
Same journal

Salute to Our Reviewers.

Journal of clinical psychopharmacology·2026
Same journal

Article Selected to Receive the Mitchell B. Balter Award for Publications in 2025.

Journal of clinical psychopharmacology·2026
Same journal

Pregnancy Outcomes After First-Trimester Exposure to Vortioxetine: Prospective Outcomes From the MGH National Pregnancy Registry for Psychiatric Medications.

Journal of clinical psychopharmacology·2026
Same journal

Salute to Our Reviewers.

Journal of clinical psychopharmacology·2026
Same journal

Serotonin Syndrome Associated With Polypharmacy in an Elderly Patient With Dementia and Parkinson Disease.

Journal of clinical psychopharmacology·2026
See all related articles

Methylphenidate did not significantly improve symptoms in schizophrenic inpatients with a history of hyperactivity. The stimulant medication showed no benefit over placebo in this short-term trial.

Area of Science:

  • Psychiatry and Behavioral Sciences
  • Clinical Pharmacology

Background:

  • Schizophrenia is a complex psychiatric disorder often presenting with persistent symptoms.
  • Some patients with schizophrenia have a history of childhood hyperactivity, suggesting potential neurodevelopmental links.
  • The use of stimulant medication in this population requires careful evaluation due to potential risks and benefits.

Purpose of the Study:

  • To investigate the efficacy of methylphenidate as an adjunctive treatment for schizophrenia.
  • To assess the impact of methylphenidate on psychiatric symptoms in patients with a history of childhood hyperactivity.

Main Methods:

  • A 2-week, double-blind, crossover study design was employed.
  • Eight male inpatients with schizophrenia on stable neuroleptic doses participated.

Related Experiment Videos

  • Standardized psychiatric rating scales (e.g., Brief Psychiatric Rating Scale) were used for assessment.

    • Main Results:

    • No statistically significant differences were observed between methylphenidate and placebo conditions across all measured scales.
    • One patient experienced a pressor effect (increased blood pressure) and was withdrawn from the study.
    • Subjective reports indicated mild improvement in three patients and slight worsening in one.

    Conclusions:

    • Methylphenidate did not demonstrate significant efficacy in improving psychiatric symptoms in this cohort of schizophrenic patients.
    • The potential for adverse cardiovascular effects, such as pressor response, should be considered.
    • Further research is needed to explore stimulant use in specific schizophrenia subpopulations.